An FDA committee is scheduled to meet in a week to review how the agency should best study the cardiovascular risks posed by ADHD drugs. Concerns were heightened by Canada's decision to pull Adderall XR from the market last year. Report [1]
Links:
[1] http://money.cnn.com/2006/02/01/news/companies/adhd/?cnn=yes